株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界における抗肥満薬市場

Global Anti-Obesity Drugs Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 320547
出版日 ページ情報 英文 72 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
世界における抗肥満薬市場 Global Anti-Obesity Drugs Market 2015-2019
出版日: 2014年11月26日 ページ情報: 英文 72 Pages
概要

世界の抗肥満薬市場は末梢作用型抗肥満薬と中枢作用型抗肥満薬の2つに区分出来ます。同市場は2014年から2019年の期間中、39.45%のCAGRで拡大する見込みです。

当レポートでは、世界の抗肥満薬市場について分析し、市場の成長展望を提供しており、市場規模の推計、FDA認可薬およびOTC薬剤の売上収益、地域別の市場情勢と成長展望、および主要ベンダープロファイルなどをまとめ、お届けいたします。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主要製品・サービス

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 発症率・罹患率

  • 米国
  • 欧州

第8章 肥満の種類

  • 単一遺伝子肥満
  • 多遺伝子肥満

第9章 肥満の原因

  • 不健康な食習慣
  • 定住性ライフスタイル
  • 特定の薬剤
  • 睡眠不足
  • 妊娠
  • 内科的疾患

第10章 肥満の分類

第11章 市場区分:薬剤クラス別

  • 末梢作用型抗肥満薬
  • 中枢作用型抗肥満薬

第12章 地域区分

第13章 購入基準

第14章 市場成長促進因子

  • 肥満罹患率の増加
  • 定住性ライフスタイルの増加
  • 大きなアンメットニーズ
  • 有望なパイプラン約・来る新薬の発売

第15章 成長因子とその影響

第16章 市場の課題

  • 高い創薬コスト
  • 不都合な副作用
  • 代替療法
  • マルチドラッグリコール

第17章 成長因子と課題の影響

第18章 市場動向

  • 激しい市場競争
  • 厳しい規制
  • 戦略的アライアンスの増加

第19章 動向とその影響

第20章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第21章 主要ベンダーの分析

  • Arena Pharmaceuticals
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Orexigen Therapeutics
  • Vivus

第22章 関連レポート

図表一覧

目次
Product Code: IRTNTR4645

About Obesity

Obesity is a medical condition in which there is surplus accumulation of fat in the body. It is linked with increased illness risk, disability, and death. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure.

TechNavio's analysts forecast the Global Anti-obesity Drugs market to grow at a CAGR of 39.45 percent over the period 2014-2019.

Covered in this Report

The Global Anti-obesity Drugs market can be divided into two segments: Peripherally Acting Anti-obesity Drugs and Centrally Acting Anti-obesity Drugs. This report covers the present scenario and the growth prospects of the Global Anti-obesity Drugs market for the period 2014-2019. To calculate the market size, the report considers the revenue generated from the sales of FDA approved drugs and OTC medications used in the treatment of obesity that are available in the market.

TechNavio's report, the Global Anti-obesity Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC and EMEA regions; it also covers the Global Anti-obesity Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Arena Pharmaceuticals
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Orexigen Therapeutics
  • Vivus

Other Prominent Vendors

  • Amylin
  • Alizyme
  • Boehringer Ingelheim
  • Eisai
  • Merck
  • Norgine
  • Novo Nordisk
  • Pfizer
  • Rhythm Pharmaceuticals
  • Shionogi USA
  • Takeda Pharmaceutical
  • Zafgan

Market Driver

  • Increased Prevalence of Obesity
  • For a full, detailed list, view our report

Market Challenge

  • High Drug Development Costs
  • For a full, detailed list, view our report

Market Trend

  • Stiff Market Competition
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Rate of Incidence and Prevalence

    • 07.1.1. US
    • 07.1.2. Europe

08. Types of Obesity

  • 08.1. Monogenic Obesity
  • 08.2. Polygenic Obesity

09. Causes of Obesity

  • 09.1. Unhealthy Eating Habits
  • 09.2. Sedentary Lifestyle
  • 09.3. Certain medications
  • 09.4. Lack of Sleep
  • 09.5. Pregnancy
  • 09.6. Medical problems

10. Classification of Obesity

11. Market Segmentation by Drug Class

  • 11.1. Peripherally Acting Anti-obesity Drugs
  • 11.2. Centrally Acting Anti-obesity Drugs

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

  • 14.1. Increase in Prevalence of Obesity
  • 14.2. Increase in Sedentary Lifestyle
  • 14.3. Significant Unmet Needs
  • 14.4. Promising Pipeline and Upcoming Launches of New Drugs

15. Drivers and their Impact

16. Market Challenges

  • 16.1. High Drug Development Costs
  • 16.2. Adverse Side Effects
  • 16.3. Alternative Treatments
  • 16.4. Multiple Drug Recalls

17. Impact of Drivers and Challenges

18. Market Trends

  • 18.1. Fierce Market Competition
  • 18.2. Strict Regulations
  • 18.3. Increase in Strategic Alliances

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2013
  • 20.3. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. Arena Pharmaceuticals
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Geographical Segmentation
    • 21.1.4. Business Strategy
    • 21.1.5. Recent Developments
    • 21.1.6. SWOT Analysis
  • 21.2. F. Hoffmann-La Roche
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Geographical Segmentation by Revenue
    • 21.2.6. Business Strategy
    • 21.2.7. Key Information
    • 21.2.8. SWOT Analysis
  • 21.3. GlaxoSmithKline
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation
    • 21.3.4. Business Segmentation by Revenue 2012 and 2013
    • 21.3.5. Sales by Geography
    • 21.3.6. Pipeline Products
    • 21.3.7. Business Strategy
    • 21.3.8. Key Information
    • 21.3.9. SWOT Analysis
  • 21.4. Orexigen Therapeutics
    • 21.4.1. Business Overview
    • 21.4.2. Business Strategy
    • 21.4.3. Recent Developments
    • 21.4.4. SWOT Analysis
  • 21.5. Vivus
    • 21.5.1. Key Facts
    • 21.5.2. Business Overview
    • 21.5.3. Business Segmentation by Revenue 2013
    • 21.5.4. Business Segmentation by Revenue 2012 and 2013
    • 21.5.5. Geographical Segmentation by Revenue 2013
    • 21.5.6. Business Strategy
    • 21.5.7. Recent Information
    • 21.5.8. SWOT Analysis

22. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Anti-obesity Drugs Market 2013-2018 (US$ million)
  • Exhibit 3: US Prevalence of Adult Overweight and Obesity (NHANES 2011-2012)
  • Exhibit 4: US Prevalence of Childhood Overweight and Obesity (NHANES 2011-2012)
  • Exhibit 5: Types of Obesity
  • Exhibit 6: Causes of Obesity
  • Exhibit 7: Global Anti-obesity Drugs Market Segmentation by Drug Class
  • Exhibit 8: Global Anti-obesity Drugs Market by Geographical Segmentation 2014
  • Exhibit 9: Arena Pharmaceuticals: Geographical Segmentation
  • Exhibit 10: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 11: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 12: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
  • Exhibit 13: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
  • Exhibit 14: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 15: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 16: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 17: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 18: Vivus: Business Segmentation by Revenue 2013
  • Exhibit 19: Vivus: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 20: Vivus: Geographical Segmentation by Revenue 2013
Back to Top